Polycystic Kidney Disease - Pipeline Review, H1 2017

Publisher Name :
Date: 09-May-2017
No. of pages: 84
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Kidney Disease - Pipeline Review, H1 2017, provides an overview of the Polycystic Kidney Disease (Genetic Disorders) pipeline landscape.

Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycystic Kidney Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 2, 14 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Polycystic Kidney Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease (Genetic Disorders).

  • The pipeline guide reviews pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Polycystic Kidney Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Polycystic Kidney Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Polycystic Kidney Disease (Genetic Disorders).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Polycystic Kidney Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Polycystic Kidney Disease - Pipeline Review, H1 2017

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Polycystic Kidney Disease - Overview
Polycystic Kidney Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Polycystic Kidney Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Polycystic Kidney Disease - Companies Involved in Therapeutics Development
3SBio Inc
Angion Biomedica Corp
Aptevo Therapeutics Inc
Conatus Pharmaceuticals Inc
DiscoveryBiomed Inc
Endocyte Inc
IC-MedTech Inc
Ipsen SA
Kadmon Corp LLC
ManRos Therapeutics
Metabolic Solutions Development Company LLC
Mironid Ltd
NovaTarg Therapeutics Inc
Otsuka Holdings Co Ltd
Q BioMed Inc
Regulus Therapeutics Inc
XORTX Pharma Corp
Polycystic Kidney Disease - Drug Profiles
(sodium ascorbate + menadione sodium bisulfite) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANG-3070 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CIM-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CR-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBM-43H11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DJ-5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Cystic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-0371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IDN-8050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JP-153 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
menadione sodium bisulfite - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSDC-0160 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxypurinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pyrimethamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGLS-4326 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate AMPK for Polycystic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PDE4 for Kidney Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STA-2842 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tesevatinib tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNFR x TWEAKR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tolvaptan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polycystic Kidney Disease - Dormant Projects
Polycystic Kidney Disease - Discontinued Products
Polycystic Kidney Disease - Product Development Milestones
Featured News & Press Releases
Mar 16, 2017: Otsuka Pharmaceutical Receives Approval for the Additional Formulation of Samsca Granules 1% in Japan
Feb 16, 2017: Regulus Announces Publication in Nature Communications Identifying miR-17 as a Promising Drug Target for ADPKD
Dec 06, 2016: Regulus Announces Update on RGLS4326
Nov 19, 2016: Kadmon to Present Additional Data Demonstrating Tesevatinib Safety for the Treatment of Polycystic Kidney Disease at ASN Kidney Week 2016
Jan 11, 2016: Scottish Medicines Consortium Issues Positive Advice For First Ever Treatment For Autosomal dominant polycystic kidney disease
Nov 02, 2015: Kadmon to Present Clinical Data on Tesevatinib for the Treatment of Polycystic Kidney Disease at ASN's Kidney Week 2015
May 28, 2015: Otsuka's JINARC the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease
Apr 14, 2015: DiscoveryBioMed is developing a novel and unprecedented "dual action" small molecule monotherapy for all cystic fibrosis (CF) patients and for other chronic larger market or rare lung and vascular diseases
Feb 27, 2015: CHMP Recommends JINARC (Tolvaptan) for Approval in EU: The First Pharmaceutical Treatment for Autosomal Dominant Polycystic Kidney Disease
Feb 26, 2015: First-Ever Treatment Approved in Canada for Adults Living with ADPKD, a Life-Threatening Kidney Disease
Sep 15, 2014: DiscoveryBioMed Awarded A Dual SBIR Awards For Drug Discovery, Validation, Optimization And Development For Autosomal Dominant Polycystic Kidney Disease, The Leading Genetic Cause Of Dialysis And Transplantation Worldwide
Jun 19, 2014: Kadmon Corporation Initiates Phase 2a Portion of KD020 Study in Autosomal Dominant Polycystic Kidney Disease
Jun 11, 2014: Otsuka Pharmaceutical Initiates Phase 3 Clinical Trial Of Tolvaptan In Patients With Autosomal Dominant Polycystic Kidney Disease
May 23, 2014: Launch in Japan of Samsca 30 mg Tablet Formulation for Patients With Autosomal Dominant Polycystic Kidney Disease, an Orphan Disease
Mar 24, 2014: Otsuka Pharmaceutical's Samsca Approved in Japan as the World's First Drug Therapy for ADPKD, a Rare Kidney Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Polycystic Kidney Disease, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Polycystic Kidney Disease - Pipeline by 3SBio Inc, H1 2017
Polycystic Kidney Disease - Pipeline by Angion Biomedica Corp, H1 2017
Polycystic Kidney Disease - Pipeline by Aptevo Therapeutics Inc, H1 2017
Polycystic Kidney Disease - Pipeline by Conatus Pharmaceuticals Inc, H1 2017
Polycystic Kidney Disease - Pipeline by DiscoveryBiomed Inc, H1 2017
Polycystic Kidney Disease - Pipeline by Endocyte Inc, H1 2017
Polycystic Kidney Disease - Pipeline by IC-MedTech Inc, H1 2017
Polycystic Kidney Disease - Pipeline by Ipsen SA, H1 2017
Polycystic Kidney Disease - Pipeline by Kadmon Corp LLC, H1 2017
Polycystic Kidney Disease - Pipeline by ManRos Therapeutics, H1 2017
Polycystic Kidney Disease - Pipeline by Metabolic Solutions Development Company LLC, H1 2017
Polycystic Kidney Disease - Pipeline by Mironid Ltd, H1 2017
Polycystic Kidney Disease - Pipeline by NovaTarg Therapeutics Inc, H1 2017
Polycystic Kidney Disease - Pipeline by Otsuka Holdings Co Ltd, H1 2017
Polycystic Kidney Disease - Pipeline by Q BioMed Inc, H1 2017
Polycystic Kidney Disease - Pipeline by Regulus Therapeutics Inc, H1 2017
Polycystic Kidney Disease - Pipeline by XORTX Pharma Corp, H1 2017
Polycystic Kidney Disease - Dormant Projects, H1 2017
Polycystic Kidney Disease - Discontinued Products, H1 2017

List of Figures

Number of Products under Development for Polycystic Kidney Disease, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting&hellip
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and&hellip
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries,&hellip
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the&hellip
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The&hellip
  • Asia-Pacific Hemodialysis Powder Solution Market Report 2017
    Published: 25-Jul-2017        Price: US 4000 Onwards        Pages: 100
    In this report, the Asia-Pacific Hemodialysis Powder Solution market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split Asia-Pacific into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Hemodialysis Powder Solution for these regions, from 2012 to 2022 (forecast), including - China - Japan ......
  • EMEA (Europe, Middle East and Africa) Hemodialysis Powder Solution Market Report 2017
    Published: 14-Jul-2017        Price: US 4000 Onwards        Pages: 101
    In this report, the EMEA Hemodialysis Powder Solution market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K MT), revenue (Million USD), market share and growth rate of Hemodialysis Powder Solution for these regions, from 2012 to 2022 (forecast) - Europe: Germany, France, UK, Russia, Ita......
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017
    Published: 11-Jul-2017        Price: US 2000 Onwards        Pages: 129
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape.Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and ches......
  • United States Hemodialysis Powder Solution Market Report 2017
    Published: 07-Jul-2017        Price: US 3800 Onwards        Pages: 104
    In this report, the United States Hemodialysis Powder Solution market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and gr......
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 05-Jul-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Acute Renal Failure (ARF) (Acute Kidney Injury) - Market Insights, Epidemiology and Market Forecast - 2025" Reports provides an overview of the disease and global market size of the Acute Renal Failure (ARF) (Acute Kidney Injury) for the 7MM (United States, Germany, France, Italy, Spain and UK). The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Acute Renal Failure (ARF) (Acute Kidney Injury) forecasted market share for ten years to......
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Insight, 2017
    Published: 05-Jul-2017        Price: US 1500 Onwards        Pages: 70
    DelveInsight's, " Chronic Kidney Disease (Chronic Renal Failure) -Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this Chronic Kidney Disease (Chronic Renal Failure). The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Chronic Kidney Disease (Chronic Renal Failure). This report provides information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failu......
  • Chronic Kidney Disease (Chronic Renal Failure) - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 05-Jul-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Chronic Kidney Disease (Chronic Renal Failure) - Market Insights, Epidemiology and Market Forecast - 2025" Reports provides an overview of the disease and global market size of the Chronic Kidney Disease (Chronic Renal Failure) for the 7MM (United States, Germany, France, Italy, Spain and UK). The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Chronic Kidney Disease (Chronic Renal Failure) forecasted market share for ten years to 20......
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Insight, 2017
    Published: 05-Jul-2017        Price: US 1500 Onwards        Pages: 70
    DelveInsight's, " Acute Renal Failure (ARF) (Acute Kidney Injury) -Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this Acute Renal Failure (ARF) (Acute Kidney Injury). The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Acute Renal Failure (ARF) (Acute Kidney Injury). This report provides information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney ......
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Epidemiology Insights to 2025
    Published: 05-Jul-2017        Price: US 2950 Onwards        Pages: 40
    DelveInsight " Acute Renal Failure (ARF) (Acute Kidney Injury) - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Acute Renal Failure (ARF) (Acute Kidney Injury) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Acute Renal Failure (ARF) (Acute Kidney Injury) prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs